What is Hypertriglyceridemia?
Hypertriglyceridemia occurs when levels of triglycerides in the blood are elevated beyond normal levels. Triglycerides are a type of fat that provide energy. When the levels of triglycerides get too high, they can cause negative health outcomes. Triglycerides levels over 150 mg/dL are considered elevated and levels over 500 mg/dL are considered severely elevated.
- Hypertriglyceridemia can be caused by various underlying medical conditions, such as diabetes, hypothyroidism, and kidney disease. It can also be caused by medications, genetic lipid disorders, and lifestyle factors.
- Hypertriglyceridemia is diagnosed through a simple blood test. It is important to consider family history, medical history, and medications when trying to identify the cause.
- Women have additional risk factors for hypertriglyceridemia, which include menopause and pregnancy.
1 in 5
Adults in the U.S. have elevated triglyceride levels.
42%
Of adults over age 60 in the U.S. have hypertriglyceridemia
Active Clinical Trials
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of ARO-APOC3 or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive ARO-APOC3.
Compassionate Use
Learn more about our compassionate use agreement and eligibility criteria for medicines in our pipeline that are currently in clinical development.
Area of Focus
Discover our areas of expertise and how we’re working to address clinical needs.
Patients & Caregivers
See how we’re advancing science to improve the lives of patients and their loved ones.
Science & Innovation
We’re relentless in our pursuit of altering the course of diseases.